clinical trial · NCT05524545
A Study of Evorpacept (ALX148) With Enfortumab Vedotin for Subjects With Urothelial Carcinoma (ASPEN-07)
Bladder CancerUrothelial CarcinomaEvorpaceptEnfortumab Vedotin
brief summary
AT148007 is a Phase 1, open-label, multicenter, safety, pharmacokinetic, pharmacodynamic study of ALX148 in combination with enfortumab vedotin and/or other anticancer therapies in subjects with urothelial carcinoma.
started
Nov 2, 2022
primary completion
Jun 27, 2025
completion
Jun 27, 2025
last updated
Jul 25, 2025
official title
A Phase 1, Open-label, Multicenter, Safety, Pharmacokinetic, Pharmacodynamic Study of ALX148 in Combination With Enfortumab Vedotin and/or Other Anticancer Therapies in Subjects With Urothelial Carcinoma (ASPEN-07)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol